Actualités réglementaires
Évolutions réglementaires FDA, EMA, TGA et mondiales
Actualités réglementaires
15 sept. 2026•1 min de lecture
Korea expands telemedicine drug delivery; 60‑day eye‑drop case
Korea is discussing broader telemedicine drug delivery after a remote prescription of a 60‑day supply of single‑use hyaluronic‑acid eye drops, sparking safety concerns.
Actualités réglementaires
15 sept. 2026•1 min de lecture
Korean Pharma Secures Minimal Buffer Amid Drug Price Cut Reassessment
The Korean pharmaceutical and biotech sector has secured a limited buffer period as the government delays and adjusts price‑cut criteria for re‑evaluated listed drugs.
Actualités réglementaires
15 sept. 2026•1 min de lecture
FDA Approves ANDA 085231 for Pyrilamine Maleate Oral Tablet by Watson Labs
The FDA granted approval for ANDA 085231, an oral tablet containing 25 mg pyrilamine maleate, submitted by Watson Labs. The product is listed as discontinued.
Actualités réglementaires
15 sept. 2026•1 min de lecture
Epic Pharma receives FDA approval for Tizanidine Hydrochloride tablets (ANDA076347)
Epic Pharma LLC's ANDA076347 for prescription oral tablets of Tizanidine Hydrochloride (2 mg and 4 mg) has been approved by the FDA, with labeling submissions approved between 2007 and 2016.
Actualités réglementaires
15 sept. 2026•1 min de lecture
FDA Approves ANDA077510 for Colestipol Hydrochloride Tablets
The FDA has approved ANDA077510 for Colestipol Hydrochloride 1 g tablets, manufactured by Amneal Pharmaceuticals and sponsored by IMPAX Labs.
Actualités réglementaires
15 sept. 2026•1 min de lecture
FDA Approves ZADITOR Ophthalmic OTC Solution (ANDA077200)
FDA has approved ZADITOR, an over‑the‑counter ophthalmic solution containing 0.025% ketotifen fumarate (application ANDA077200).
Actualités réglementaires
15 sept. 2026•1 min de lecture
FDA Approves Multiple Labeling Supplements for MirtaZAPINE (ANDA 076901)
FDA's ANDA 076901 for MirtaZAPINE includes three discontinued oral tablet strengths and a series of approved labeling supplements dating from 2005 to 2025.
Actualités réglementaires
14 sept. 2026•1 min de lecture
Korean Lawmaker Proposes Health‑Medical Regulatory Sandbox Amendment
Lawmaker Kwon Chil‑seung filed an amendment to the Health and Medical Technology Promotion Act to establish a regulatory sandbox for health‑medical innovations.
Actualités réglementaires
14 sept. 2026•1 min de lecture
Korean Lawmakers Urge Prioritizing Rare Disease Policies
Lawmakers and the Korean Rare & Intractable Disease Association held a press conference urging that rare disease patients not be sidelined in policy priorities.
Actualités réglementaires
14 sept. 2026•1 min de lecture
Indonesian BPOM delegation visits Daewoong Pharma’s Magok R&D center to explore collaboration
An Indonesian BPOM pharmaceutical delegation toured Daewoong Pharmaceutical’s Magok R&D facility, reviewing new‑drug and biopharma projects and discussing joint development and approval pathways in Indonesia.
Actualités réglementaires
14 sept. 2026•1 min de lecture
Korea's first domestically developed CAR‑T therapy Rimkato clears drug reimbursement evaluation
The domestically developed CAR‑T drug Rimkato (Anbalcapatgen Autolyscel) cleared the drug reimbursement evaluation committee, moving closer to inclusion in national health‑insurance coverage.
Actualités réglementaires
14 sept. 2026•1 min de lecture
Seoul Pharmacists Association Calls for Fast Legislative Action on Pharmacy Independence and Drug Safety
The Seoul Pharmacists Association delivered a petition to the National Assembly urging prompt review of pending pharmacist‑related bills and stressing safety checks before expanding telemedicine drug delivery.